AF
NAGE

Amalgamated Financial’s Niagen Bioscience NAGE Stock Holding History

Amalgamated Financial’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$19K Buy
+7,631
New +$20.9K ﹤0.01% 2764

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $119M AUM 233.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Amalgamated Financial's NAGE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Niagen Bioscience (NAGE) in Q1 2022: 7,631 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #2764 among its holdings.

82 funds tracked by Wall St. Rank hold NAGE as of Q1 2022.

  • Amalgamated Financial held 7,631 shares of Niagen Bioscience worth $19K as of Q1 2022.
  • Niagen Bioscience was a new Amalgamated Financial position in Q1 2022.
  • Niagen Bioscience made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2764 holding.
  • 82 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.